Skip to main content

DarioHealth Corp

For the period ended Mar 31, 2024. Filed May 15, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 15, 2024

DRIO$2.39+16.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Interim Consolidated Statements of Cash Flows

U.S. dollars in thousands

​​​​​​​
​ · ​ · Three months ended
​ · ​ · March 31,
​ · 2024 · 2023
​​Unaudited
Cash flows from operating activities:​​​​​​
Net loss​$(7,175)​$(12,825)
Adjustments required to reconcile net loss to net cash used in operating activities:​​​​
Stock-based compensation, common stock, and payment in stock to directors, employees, consultants, and service providers​6,858​4,856
Depreciation​110​97
Change in operating lease right of use assets​149​36
Amortization of acquired intangible assets​1,216​1,113
Decrease (increase) in trade receivables​(1,401)​3,619
Increase in other accounts receivable, prepaid expense and long-term assets​(1,866)​(892)
Decrease in inventories​146​1,079
Increase (decrease) in trade payables​708​(439)
Decrease in other accounts payable and accrued expenses​(2,620)​(621)
Decrease in deferred revenues​52​(395)
Change in operating lease liabilities​(18)​(78)
Change in fair value of warrant liability​(9,181)​(80)
Non-Cash financial income​(83)​(227)
Other​(5)​—
​​​​​​​
Net cash used in operating activities​(13,110)​(4,757)
​​​​​​​
Cash flows from investing activities:​​
Purchase of property and equipment​(56)​(74)
Purchase of short-term investments​​-​​(4,996)
Proceeds from redemption of short-term investments​​-​​708
Payments for business acquisitions, net of cash acquired​​(8,796)​​-
​​​​​​​
Net cash used in investing activities​(8,852)​(4,362)
​​​​​​​
Cash flows from financing activities:​​​​
Proceeds from issuance of preferred stock, net of issuance costs​20,206​-
Principal payments on long-term loan​-​(1,389)
​​​​​​​
Net cash provided by financing activities​20,206​(1,389)
​​​​​​​
Increase in cash, cash equivalents and restricted cash and cash equivalents​(1,756)​(10,508)
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period​36,797​49,470
Cash, cash equivalents and restricted cash and cash equivalents at end of period​$35,041​$38,962
Supplemental disclosure of cash flow information:​​​
Cash paid during the period for interest on long-term loan​$986​$1,072
Non-cash activities:​​​
Right-of-use assets obtained in exchange for lease liabilities​$28​$28
​​​​​​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.